^
    over3years
    Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. (PubMed, Cancer Immunol Immunother)
    In conclusion, S-588410 induces a tumor immune response in esophageal cancer. Induction of CD8+ PD-1+ tumor-infiltrating lymphocytes and PD-L1 expression in the TME by vaccination suggests S-588410 in combination with anti-PD-(L)1 antibodies may offer a clinically useful therapy.Trial registration UMIN-CTR registration identifier: UMIN000023324.
    Clinical • Journal • Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
    |
    PD-L1 expression • TILs
    |
    asudemotide (S-588410)